Sally Stenning

17.7k total citations · 3 hit papers
120 papers, 11.5k citations indexed

About

Sally Stenning is a scholar working on Surgery, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Sally Stenning has authored 120 papers receiving a total of 11.5k indexed citations (citations by other indexed papers that have themselves been cited), including 61 papers in Surgery, 45 papers in Pulmonary and Respiratory Medicine and 22 papers in Oncology. Recurrent topics in Sally Stenning's work include Testicular diseases and treatments (46 papers), Gastric Cancer Management and Outcomes (18 papers) and Urologic and reproductive health conditions (16 papers). Sally Stenning is often cited by papers focused on Testicular diseases and treatments (46 papers), Gastric Cancer Management and Outcomes (18 papers) and Urologic and reproductive health conditions (16 papers). Sally Stenning collaborates with scholars based in United Kingdom, Norway and Netherlands. Sally Stenning's co-authors include Ruth E. Langley, William Allum, David Cunningham, Stephen Falk, M. Nicolson, Monica Verma, J N Thompson, J.H. Scarffe, Cornelis J.�H. van de Velde and F. Lofts and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Sally Stenning

117 papers receiving 11.2k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer

2006 4.5k citations David Cunningham, William Allum et al. profile →
Long-Term Results of a Randomized Trial of Surgery With or Without Preoperative Chemotherapy in Esophageal Cancer

2009 721 citations William Allum, Sally Stenning et al. Journal of Clinical Oncology profile →
Mismatch Repair Deficiency, Microsatellite Instability, and Survival

2017 365 citations Elizabeth Smyth, Andrew Wotherspoon et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Sally Stenning	6.6k	6.6k	2.2k	1.9k	1.5k	120	11.5k
A. Norman	5.2k 0.8×	5.9k 0.9×	5.9k 2.6×	1.0k 0.6×	508 0.3×	138	12.3k
Manjit S. Bains	8.0k 1.2×	12.0k 1.8×	3.6k 1.6×	645 0.3×	1.6k 1.0×	307	16.6k
Rosalba Miceli	2.6k 0.4×	5.4k 0.8×	4.5k 2.0×	648 0.3×	989 0.7×	251	10.6k
Andrew K. Stewart	5.8k 0.9×	4.6k 0.7×	7.6k 3.4×	284 0.2×	530 0.3×	166	15.1k
Barry W. Feig	7.8k 1.2×	7.3k 1.1×	9.2k 4.1×	1.2k 0.6×	649 0.4×	323	17.4k
Lene Mellemkjær	1.9k 0.3×	1.5k 0.2×	2.6k 1.2×	249 0.1×	522 0.3×	209	11.4k
Clive S. Grant	9.7k 1.5×	1.7k 0.3×	5.3k 2.4×	286 0.2×	1.9k 1.3×	261	19.4k
Xuemei Wang	1.8k 0.3×	3.1k 0.5×	2.8k 1.3×	308 0.2×	279 0.2×	252	10.4k
Graça M. Dores	1.9k 0.3×	1.9k 0.3×	2.9k 1.3×	252 0.1×	446 0.3×	83	8.1k
Martee L. Hensley	1.6k 0.2×	4.7k 0.7×	4.2k 1.8×	238 0.1×	244 0.2×	223	13.3k

Countries citing papers authored by Sally Stenning

Since Specialization

Citations

This map shows the geographic impact of Sally Stenning's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sally Stenning with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sally Stenning more than expected).

Fields of papers citing papers by Sally Stenning

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sally Stenning. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sally Stenning. The network helps show where Sally Stenning may publish in the future.

Co-authorship network of co-authors of Sally Stenning

This figure shows the co-authorship network connecting the top 25 collaborators of Sally Stenning. A scholar is included among the top collaborators of Sally Stenning based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sally Stenning. Sally Stenning is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cragg, William J, et al.. (2021). Dynamic methods for ongoing assessment of site-level risk in risk-based monitoring of clinical trials: A scoping review. Clinical Trials. 18(2). 245–259. 6 indexed citations

Cragg, William J, et al.. (2020). Assessing the potential for prevention or earlier detection of on-site monitoring findings from randomised controlled trials: Further analyses of findings from the prospective TEMPER triggered monitoring study. Clinical Trials. 18(1). 115–126. 1 indexed citations

Smyth, Elizabeth, Shenli Zhang, David Cunningham, et al.. (2017). Pharmacogenetic Analysis of the UK MRC (Medical Research Council) MAGIC Trial: Association of Polymorphisms with Toxicity and Survival in Patients Treated with Perioperative Epirubicin, Cisplatin, and 5-fluorouracil (ECF) Chemotherapy. Clinical Cancer Research. 23(24). 7543–7549. 9 indexed citations

McNeish, Iain A., Andrew Dean, David Gallardo, et al.. (2017). ICON8: A GCIG phase III randomised trial evaluating weekly dose- dense chemotherapy integration in first-line epithelial ovarian/fallopian tube/primary peritoneal carcinoma (EOC) treatment: Results of primary progression- free survival (PFS) analysis. Annals of Oncology. 28. v627–v627. 38 indexed citations

Smyth, Elizabeth, Samuel Rowley, William Allum, et al.. (2016). A randomised phase II study of perioperative epirubicin, cisplatin and capecitabine (ECX) ± lapatinib for operable, HER-2 positive gastric, oesophagogastric junctional (OGJ) or lower oesophageal adenocarcinoma: Results from the UK MRC ST03 lapatinib feasibility study (ISRCTN 46020948). Annals of Oncology. 27. vi562–vi562. 2 indexed citations

Gilbert, Duncan C., Reem Al‐Saadi, Khin Thway, et al.. (2015). Defining a New Prognostic Index for Stage I Nonseminomatous Germ Cell Tumors Using CXCL12 Expression and Proportion of Embryonal Carcinoma. Clinical Cancer Research. 22(5). 1265–1273. 18 indexed citations

Cunningham, David, Ruth E. Langley, Matthew Nankivell, et al.. (2015). LBA-03 Neoadjuvant chemotherapy for resectable oesophageal and junctional adenocarcinoma: results from the UK Medical Research Council randomised OEO5 trial (ISRCTN 01852072). Annals of Oncology. 26. iv117–iv117. 7 indexed citations

Stenning, Sally, et al.. (2013). Update on the temper study: targeted monitoring, prospective evaluation and refinement. Trials. 14(S1). 2 indexed citations

Okines, Alicia, Lindsay C Thompson, David Cunningham, et al.. (2012). Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial. Annals of Oncology. 24(5). 1253–1261. 70 indexed citations

10.

Oliver, R. Timothy D., Graham M. Mead, Gordon Rustin, et al.. (2011). Randomized Trial of Carboplatin Versus Radiotherapy for Stage I Seminoma: Mature Results on Relapse and Contralateral Testis Cancer Rates in MRC TE19/EORTC 30982 Study (ISRCTN27163214). Journal of Clinical Oncology. 29(8). 957–962. 178 indexed citations

11.

Brada, Michael, Sally Stenning, Rhian Gabe, et al.. (2010). Temozolomide Versus Procarbazine, Lomustine, and Vincristine in Recurrent High-Grade Glioma. Journal of Clinical Oncology. 28(30). 4601–4608. 178 indexed citations

12.

Sydes, Matthew R., John Radford, Barry W. Hancock, et al.. (2009). Initial dose intensity has limited impact on the outcome of ABVD chemotherapy for advanced Hodgkin lymphoma (HL): data from UKLG LY09 (ISRCTN97144519). Annals of Oncology. 21(3). 568–573. 9 indexed citations

13.

Sydes, Matthew R., et al.. (2008). Myeloablative therapy for recurrent Hodgkin lymphoma: Good success rates irrespective of previous treatments in the UKLG LY09 trial (ISRCTN97144519). ePrints Soton (University of Southampton). 2 indexed citations

14.

Huddart, Robert, Michael O’Doherty, Anwar R. Padhani, et al.. (2007). ¹⁸ Fluorodeoxyglucose Positron Emission Tomography in the Prediction of Relapse in Patients With High-Risk, Clinical Stage I Nonseminomatous Germ Cell Tumors: Preliminary Report of MRC Trial TE22—The NCRI Testis Tumour Clinical Study Group. Journal of Clinical Oncology. 25(21). 3090–3095. 68 indexed citations

15.

Stenning, Sally, et al.. (2005). Radical prostatectomy: pathology compared with other major series findings in 1001 cases and over time. UCL Discovery (University College London).

16.

Beyer, J., Sally Stenning, A. Gerl, S.D. Fosså, & W. Siegert. (2002). High-dose versus conventional-dose chemotherapy asfirst-salvage treatment in patients with non-seminomatousgerm-cell tumors: a matched-pair analysis. Annals of Oncology. 13(4). 599–605. 78 indexed citations

17.

Mead, Graham M., Matthew R. Sydes, Jan Walewski, et al.. (2002). An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt’s lymphoma: results of United Kingdom Lymphoma Group LY06 study. Annals of Oncology. 13(8). 1264–1274. 212 indexed citations

18.

Karim, Abul B.M.F., D Afra, Philippe Cornu, et al.. (2002). Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European Organization for Research and Treatment of Cancer Study 22845 with the Medical Research Council study BRO4: an interim analysis. International Journal of Radiation Oncology*Biology*Physics. 52(2). 316–324. 288 indexed citations

19.

Beyer, J., et al.. (1999). High-dose versus conventional-dose first-salvage treatment in nonseminoma: a matched-pair analysis. UCL Discovery (University College London). 11 indexed citations

20.

Wit, Ronald de, Paul Wilkinson, PHM de Mulder, et al.. (1999). Is 3BEP equivalent to 3BEP+1EP in good prognosis germ cell cancer? An EORTC/MRC phase III study. UCL Discovery (University College London). 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact